TheEdgeResearch
Home / Stocks / PRNAF

Alterity Therapeutics Limited (PRNAF)

OTC Healthcare Biotechnology
$0.14 ▼ -30.40%
Market Cap
$31.9M
Sector
Healthcare
Industry
Biotechnology
Beta
-0.04
52-Wk Range
0.0002-0.5501
CEO
David A. Stamler
Country
AU
Currency
USD

Alterity Therapeutics Limited operates in the Biotechnology industry of the Healthcare sector, headquartered in Melbourne, VIC, AU. The stock last traded at $0.14, down 30.40% on the session, giving a market capitalisation of $31.9M. On trailing twelve-month figures it carries a trailing P/E of -1.68, a net margin of 0.0%. Its beta of -0.04 implies it has historically moved less than the broad market.

Valuation & profitability (TTM)
P/E
-1.68
Price / Sales
0.00
Price / Book
0.94
EV / EBITDA
-0.19
Gross margin
0.0%
Operating margin
0.0%
Net margin
0.0%
Return on equity
—
Debt / equity
0.00
Current ratio
14.52
Dividend yield
0.0%
Payout ratio
0.0%
Company profile
Exchange
Other OTC
Employees
11
IPO date
2012-09-25
Headquarters
Melbourne, VIC, AU
About Alterity Therapeutics Limited

Based in Melbourne, Australia, Alterity Therapeutics Limited, founded in 1997, is dedicated to the discovery and advancement of treatments for neurological conditions such as Alzheimer's, Huntington's, and Parkinson's diseases, among others. The company's primary drug candidate, ATH434, has successfully navigated Phase I clinical trials for Parkinson's disease. Additionally, it is progressing PBT2, an investigational compound for Alzheimer's disease that has completed Phase 2a clinical trials. The firm, previously known as Prana Biotechnology Limited, adopted its current name, Alterity Therapeutics Limited, in April 2019.

More research on PRNAF
PRNAF technical analysis PRNAF TheEdge Score Compare against peers
Open full interactive analysis & DCF →